Politics, science and remarkable race for a coronavirus vaccine


The President was particularly excited about this goal. At a White House meeting on March 2, as Mr Bancel and other pharmaceutical executives outlined their vaccination plans, Dr Fauci warned that it would take “a year to a year and a half” before doses can reach the general public.

Mr. Trump replied, “I like the sound of a few months better.”

Warp Speed ​​had two leaders. Dr Slaoui was head of science, who had led research and development at drug maker GlaxoSmithKline for years and served on Moderna’s board. General Gustave F. Perna, a four-star general who headed the Army Materiel Command, was responsible for logistics.

ALSO READ  Arizona School District Cancels Classes After Mass Sickout Over Virus Concerns

The operation, which took place in a suite on the seventh floor and an operations center on the second floor at Health and Human Services Headquarters, had a military flavor. Its leaders discussed the book “Freedom’s Forge,” an account of how American industry armed the military during World War II, and imposed what they called a “combat rhythm” of meetings. , including a daily 8 hour session on vaccines. Dozens of military officers reported working in uniform.

ALSO READ  Amazon Prime Air: FAA gives approval for drone deliveries

The most important decision, Dr Slaoui said, was which vaccine candidates to choose from the nearly 50 possible candidates. His team chose three types of vaccines, each to be used by two companies if one company fails. Federal officials called the finalists “horses,” a nod to the race between them.

Moderna and Pfizer would pursue mRNA vaccines, considered the fastest to develop. The government was prepared to pay a large chunk of the development bill, guide clinical trials, and even deliver supplies to factories.

ALSO READ  In the face of grim polls, Trump leans in to play victim

Dr Bourla was not interested. As one of the world’s largest vaccine producers, Pfizer did not need the help of the federal government to develop a new product, he decided, and with nearly $ 52 billion in annual revenue. , he didn’t need or want the grant.

“If we fail, we will have to write off $ 2 billion” in vaccine development costs, Dr Bourla said at the New York Times DealBook online summit this week. “It’s painful for any business, but it wasn’t going to break us.”


Please enter your comment!
Please enter your name here